Physico-chemical and Biopharmaceutical Investigations of Novel Drug Delivery Systems for Oral Administration of Lipophilic Drugs

用于口服亲脂性药物的新型给药系统的理化和生物制药研究

• 批准号: DP0558920
• 负责人: Prof Clive Prestidge
• 金额: $ 18.02万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-04-05 至 2008-05-01
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0558920
• 关键词: Physico; chemical; Biopharmaceutical; Investigations; Novel

The new platform technology for carrying lipophilic molecules will be applicable to many molecules currently under development by Australian Industry and will inspire novel encapsulation approaches to new and existing drugs as well as functional foods and nutraceuticals. Improved oral bioavailability of anticancer drugs will improve the quality of life of patients, reduce health care costs and provide broader benefits to the community. The Australian biotechnology/pharmaceutical industries can share in a greater proportion of the US$50 billion market for specialised drug delivery, which is increasing by 20% annually. Australia's scientific competitiveness will be strengthened in the fields of nano-encapsulation and colloidal delivery.

携带亲脂分子的新平台技术将适用于澳大利亚工业公司目前正在开发的许多分子，并将启发新的和现有的药物以及功能食品和营养食品的新的封装方法。提高抗癌药物的口服生物利用度将提高患者的生活质量，降低医疗成本，为社会提供更广泛的好处。澳大利亚生物技术/制药行业可以在美国500亿美元的专业药物输送市场中占有更大份额，该市场每年以20%的速度增长。澳大利亚在纳米胶囊和胶体输送领域的科学竞争力将得到加强。